GSK836 (Bepirovirsen): A Groundbreaking Therapy for Chronic Hepatitis B Set for 2026 Launch

As mentioned earlier, we know that the hepatitis B virus forms covalently closed circular DNA (cccDNA) in the nucleus, and the cccDNA's stability and difficulty to be eliminated are the main reasons why hepatitis B is hard to cure. According to relevant reports, the most promising drug currently under research is Bepirovirsen (GSK836), a new hepatitis B drug being developed by GlaxoSmithKline (GSK), also commonly referred to as 836. This has become a beacon of hope for many hepatitis B carriers. Today, let’s take a look at the latest information on GSK836.

According to official information released by GlaxoSmithKline (GSK), GSK836 is expected to submit a regulatory application in 2026 and is likely to receive a regulatory decision in the same year, becoming a significant breakthrough in the field of hepatitis B treatment.That is, it will be launched as early as 2026!This drug is an antisense oligonucleotide (ASO) drug, which belongs to small molecule drugs and is mainly used for the treatment of chronic hepatitis B (HBV).The drug's mechanism of action involves the inhibition of key enzymes in the gene expression of the hepatitis B virus, blocking the viral replication process, thereby reducing or eliminating the viral load in the body.The drug has been granted the designations of "Breakthrough Therapy Program," "Fast Track," and "SENKU (formerly known as SAKIGAKE)" in China, the United States, and Japan, which means that these regions will give priority to its approval process.

Clinical Trials and Efficacy Data

Currently, the complete data of the ongoing Phase III clinical trial of GSK836 is expected to be released in 2016. However, the company may present partial data at several hepatology conferences, such as the 2025 Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting, the European Association for the Study of the Liver (EASL) Annual Meeting, and the American Association for the Study of Liver Diseases (AASLD) Annual Meeting. Earlier Phase IIb clinical trials (B-Clear study) showed,After 24 weeks of treatment with GSK836, approximately 30% of patients with chronic hepatitis B achieved dual clearance of hepatitis B surface antigen (HBsAg) and HBV DNA.And 24 weeks after discontinuation of the drug, about 10% of patients maintained this effect. Particularly in some patient groups who are hepatitis B e-antigen (HBeAg) negative and have HBsAg ≤3000 IU/ml, the effect of sustained HBsAg and HBV DNA clearance could be maintained long-term after stopping the medication. These are patients with chronic hepatitis B virus infection—those with "small three positives" (minor markers positive), whose surface antigen is below 1500, considered an advantageous group for interferon treatment while waiting for new drugs. After all, the side effects, high costs, and low success rates associated with interferon therapy are major obstacles for many patients.

Beneficiaries and Potential

The Phase III clinical trial of GSK836 will specifically focus on patients who are baseline hepatitis B e-antigen negative, with HBsAg ≤3000 IU/ml but above 100 IU/ml. This population has shown a better response to GSK836 treatment, and the drug is expected to demonstrate even more significant clinical outcomes in these patients. If GSK836 is approved, it is anticipated to deliver substantial therapeutic benefits for this group, potentially eliminating the burden of hepatitis B virus and lifelong medication. Additionally, data indicates that GSK836 has low resistance, with almost no occurrence of resistance mutations observed during the trial.

Future Prospects and Market Impact

Once GSK836 is approved, it may completely transform the treatment landscape for chronic hepatitis B. Current treatments for hepatitis B mainly rely on interferons and nucleos(t)ide analogs, which typically require lifelong administration. However, the efficacy of GSK836 could potentially free some patients from lifelong medication dependence and might even lead to a complete cure for the hepatitis B virus. The launch of GSK836 will mark a revolution in the field of hepatitis B treatment, breaking the market dominance of existing drugs and bringing new hope to hepatitis B patients worldwide.